We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Multicenter Selective Lymphadenectomy Trial II (MSLT-II)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00297895
Recruitment Status : Active, not recruiting
First Posted : March 1, 2006
Last Update Posted : August 18, 2017
Information provided by (Responsible Party):

February 27, 2006
March 1, 2006
August 18, 2017
September 2004
September 2022   (Final data collection date for primary outcome measure)
Melanoma-specific survival. This is defined as the time between the date of a subject's randomization (or date of CLND for those randomized to the CLND arm) and the date of death due to melanoma. Subjects are followed until death or 10yrs. [ Time Frame: 10 years ]
Melanoma-specific survival. This is defined as the time between the date of a subject's randomization (or date of CLND for those randomized to the CLND arm) and the date of death due to melanoma. Subjects are followed until death or 10yrs.
Complete list of historical versions of study NCT00297895 on ClinicalTrials.gov Archive Site
  • Disease-free survival over 10 years of follow up [ Time Frame: 10 years ]
  • Recurrence during 10 years of follow up [ Time Frame: 10 years ]
  • Disease-free survival over 10 years of follow up
  • Recurrence during 10 years of follow up
Not Provided
Not Provided
Multicenter Selective Lymphadenectomy Trial II (MSLT-II)
A Phase III Multicenter Randomized Trial of Sentinel Lymphadenectomy and Complete Lymph Node Dissection Versus Sentinel Lymphadenectomy Alone in Cutaneous Melanoma Patients With Molecular or Histopathological Evidence of Metastases in the Sentinel Node
Subjects must be diagnosed with melanoma. All subjects receive sentinel lymphadenectomy. If the subject is sentinel node positive and meets study requirements, the subject is randomized to receive either (1) completion lymphadenectomy (2) observation with nodal ultrasound. Subjects are then followed for 10 years.
Not Provided
Not Provided
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
  • Procedure: Completion Lymphadenectomy
    complete lymph node dissection of lymph node basin with positive node
  • Procedure: Monitoring with nodal ultrasound
    serial ultrasound monitoring of SLND positive basin. If recurrence detected, subject has CLND.
  • Active Comparator: Ultrasound observation + delayed CLND if recurrence detected
    Intervention: Procedure: Monitoring with nodal ultrasound
  • Active Comparator: CLND
    Intervention: Procedure: Completion Lymphadenectomy
Faries MB, Thompson JF, Cochran AJ, Andtbacka RH, Mozzillo N, Zager JS, Jahkola T, Bowles TL, Testori A, Beitsch PD, Hoekstra HJ, Moncrieff M, Ingvar C, Wouters MWJM, Sabel MS, Levine EA, Agnese D, Henderson M, Dummer R, Rossi CR, Neves RI, Trocha SD, Wright F, Byrd DR, Matter M, Hsueh E, MacKenzie-Ross A, Johnson DB, Terheyden P, Berger AC, Huston TL, Wayne JD, Smithers BM, Neuman HB, Schneebaum S, Gershenwald JE, Ariyan CE, Desai DC, Jacobs L, McMasters KM, Gesierich A, Hersey P, Bines SD, Kane JM, Barth RJ, McKinnon G, Farma JM, Schultz E, Vidal-Sicart S, Hoefer RA, Lewis JM, Scheri R, Kelley MC, Nieweg OE, Noyes RD, Hoon DSB, Wang HJ, Elashoff DA, Elashoff RM. Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma. N Engl J Med. 2017 Jun 8;376(23):2211-2222. doi: 10.1056/NEJMoa1613210.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
Active, not recruiting
September 2022
September 2022   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Ability to provide informed consent.
  2. Between 18 and 75 years of age.
  3. Have a primary melanoma that is cutaneous (including head, neck, trunk, extremity, scalp, palm, sole, subungual skin tissues).
  4. Have clear margins following WLE.
  5. ECOG performance status 0-1.
  6. Life expectancy of at least 10 years from the time of diagnosis, not considering the melanoma in question, as determined by the PI.
  7. Willing to return to the MSLT-II center for follow up examinations and procedures as outlined in the protocol.
  8. Randomization and/or CLND (as appropriate to randomization arm) must be completed no more than 120 days following the diagnostic biopsy of the primary melanoma.
  9. Have a melanoma-related tumor-positive SN, determined by either of the following methods:

    1. Diagnosis of tumor-positive SN by MSLT-II center institutional pathologist by either H&E or IHC (using S-100, Mart-1, and HMB-45).
    2. Diagnosis of tumor-positive SN by RT-PCR analysis performed at JWCI, provided the primary melanoma fits into one of the following categories:

      • Breslow thickness of 1.20 mm or greater and Clark Level III
      • Clark Level IV or V, regardless of Breslow thickness
      • Ulceration, regardless of Breslow thickness or Clark level

Exclusion Criteria:

  1. History of previous or concurrent (i.e., second primary) invasive melanoma.
  2. Primary melanoma of the eye, ears, mucous membranes or internal viscera. (Primary of the skin of the external ear is acceptable.)
  3. Physical, clinical, radiographic or pathologic evidence of satellite, in-transit, regional, or distant metastatic disease.
  4. Any additional solid tumor or hematologic malignancy during the past 5 years except T1 skin lesions of squamous cell carcinoma, basal cell carcinoma, or uterine cervical cancer.
  5. Skin grafts, tissue transfers or flaps that have the potential to alter the lymphatic drainage pattern from the primary melanoma to a LN basin.
  6. Allergy to vital blue dye or any radiocolloid.
  7. Inability to localize 1-2 SN drainage basins via LM (e.g., no basins found, more than 2 basins found, proximity of the primary melanoma to the regional draining basin, etc.)
  8. CLNDs or SLs (before evaluation of the current melanoma) that may have altered the lymphatic drainage pattern from the primary cutaneous melanoma to a potential LN basin.
  9. Organic brain syndrome or significant impairment of basal cognitive function or any psychiatric disorder that might preclude participation in the full protocol, or be exacerbated by therapy (e.g., severe depression).
  10. Melanoma-related operative procedures not corresponding to criteria described in the protocol.
  11. Primary or secondary immune deficiencies or known significant autoimmune disease.
  12. History of organ transplantation.
  13. Oral or parenteral immunosuppressive agents (not topical or inhaled steroids) at any time during study participation or within 6 months prior to enrollment.
  14. Pregnant or lactating women.
  15. Participation in concurrent therapy protocols of alternative local nodal basin therapies that might confound the analysis of this trial is not permitted. For example, radiation of a non-resected node basin is not acceptable because it might influence outgrowth of residual melanoma in that nodal basin. However, systemic adjuvant therapy or clinical trial adjuvant protocols after the finding of a positive node on LM/SL or delayed nodal recurrence in the ultrasound observation arm are both acceptable according to the standard of care at the multicenter site. Patients with positive sentinel nodes or thick primary melanomas who are considered by the multicenter site's investigator as high-risk may receive systemic adjuvant therapy according to the standard practice of that particular site.
  16. SLND pathology shows, on microscopic examination, that melanoma extends through the lymph node capsule into the adjacent soft tissue.
Sexes Eligible for Study: All
18 Years to 75 Years   (Adult, Senior)
Contact information is only displayed when the study is recruiting subjects
Australia,   Canada,   Finland,   Germany,   Israel,   Italy,   Netherlands,   Spain,   Sweden,   Switzerland,   United Kingdom,   United States
P01CA029605 ( U.S. NIH Grant/Contract )
R01CA189163 ( U.S. NIH Grant/Contract )
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Plan to Share IPD: Undecided
John Wayne Cancer Institute
John Wayne Cancer Institute
  • National Institutes of Health (NIH)
  • National Cancer Institute (NCI)
Study Chair: Mark B. Faries, M.D. John Wayne Cancer Institute
John Wayne Cancer Institute
August 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP